Q-omics provides the consensus-scored MT1JP profile across patient tissues and cancer cell-line models. MT1JP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MT1JP is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MT1JP RNA expression shows 8,055 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, COAD, and TGCT as cancer lineages where MT1JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1JP survival associations across molecular data types. MT1JP RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1JP RNA expression–survival associations across cancer types. High MT1JP expression shows unfavorable associations in LGG, KIRP, UCEC, KIRC, ESCA and LUSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MT1JP RNA expression.
This table summarizes MT1JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MT1JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1JP shows lower tumor expression in COAD, LUAD, LIHC, KICH, KIRP and BRCA. The COAD box plot shows higher MT1JP RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with MT1JP in patient tissues and cancer cell lines. In patient samples, MT1JP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
